What is NexImmune Price-to-Operating-Cash-Flow?
As of today (2024-04-29), NexImmune's share price is $3.335.
NexImmune's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-29.99. Hence, NexImmune's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for NexImmune's Price-to-Operating-Cash-Flow or its related term are showing as below:
NexImmune's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $-5.48.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-29.99.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 3.50% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -5.40% per year.
During the past 6 years, NexImmune's highest 3-Year average Operating Cash Flow per Share Growth Rate was 3.50% per year. The lowest was -25.90% per year. And the median was -12.30% per year.
NexImmune Price-to-Operating-Cash-Flow Historical Data
The historical data trend for NexImmune's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NexImmune Price-to-Operating-Cash-Flow Chart
|
NexImmune Annual Data
|
|
Trend |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
- |
- |
- |
- |
- |
|
NexImmune Quarterly Data
|
|
Dec18 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of NexImmune's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, NexImmune's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NexImmune's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NexImmune's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where NexImmune's Price-to-Operating-Cash-Flow falls into.
NexImmune Price-to-Operating-Cash-Flow Calculation
NexImmune's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 3.335 | / | -29.99 |
| = | |
NexImmune's Share Price of today is $3.335.
NexImmune's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.99.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
NexImmune (NexImmune) Business Description
Traded in Other Exchanges
N/A
Address
9119 Gaither Road, Gaithersburg, MD, USA, 20877
NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
Executives
| Alan S. Roemer |
director |
C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018 |
| Timothy Stover |
officer: VP, Corporate Controller |
C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
| Sol J Barer |
director |
C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116 |
| Zhengbin Yao |
director |
10301 STELLA LINK ROAD, HOUSTON TX 77025 |
| Leena Gandhi |
director |
C/O NEXIMMUNE, 9119 GAITHER ROAD, GAITHERSBURG MD 20878 |
| Timothy Bertram |
director |
C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403 |
| Paul D'angio |
director |
C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
| Grant Verstandig |
director |
C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
| Mathias Oelke |
officer: Chief Science Officer |
C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20878 |
| Kristi Jones |
officer: Chief Operating Officer |
C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
| Jerome B Zeldis |
officer: EVP of R&D |
8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258 |
| Scott Carmer |
director, officer: President and CEO |
C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
| John Trainer |
officer: Chief Financial Officer |
C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
| Robert Douglas Knight |
officer: Chief Medical Officer |
C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
NexImmune (NexImmune) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NEXI has been successfully added to your